{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:30:01Z","timestamp":1790195401816,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite achieving sustained virologic response (SVR) after treatment with direct-acting antivirals (DAAs), patients with hepatitis C virus (HCV)-related cirrhosis remain at risk of hepatocellular carcinoma (HCC) development. Glypican-3 (GPC-3) is a heparan sulfate proteoglycan with oncogenic role in HCC. This study aimed to assess the diagnostic and prognostic value of serum GPC-3 in patients with HCV-related cirrhosis who achieved SVR following DAA therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective, observational study including 832 patients with HCV-related cirrhosis treated with DAAs between 2014 and 2024. Patients were divided into two cohorts: cohort A (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009551) without HCC at enrolment and cohort B (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009281) with established HCC. Serum GPC-3 was measured using a commercially available enzyme immunoassay (CanAg Glypican-3 EIA, Fujirebio Diagnostics AB, Gothenburg, Sweden).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analyzed 832 single serum samples: collected at SVR12 in Cohort A and at HCC diagnosis in Cohort B. GPC-3 levels were significantly higher in patients with HCC compared to those without (95, 50\u2013185\u00a0pg\/mL vs. 48, 29\u201379\u00a0pg\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with moderate diagnostic accuracy (AUC\u2009=\u20090.711). During follow-up (37, 20\u201351\u00a0months), GPC-3 levels did not predict the development of de novo HCC in cohort A. However, in cohort B, GPC-3\u2009&gt;\u2009150\u00a0pg\/mL was independently associated with reduced survival (adjusted HR\u2009=\u20091.68, 95% CI 1.03\u20132.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While GPC-3 may be of limited utility for predicting HCC occurrence in patients cured of HCV, it could represent a valuable prognostic factor able to predict survival of patients with established HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-025-01371-0","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:52:13Z","timestamp":1767963133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective Analysis of Diagnostic and Prognostic Value of Serum Glypican-3 in Patients With HCV-Related Cirrhosis With Or Without HCC After Achieving SVR With DAA Treatment"],"prefix":"10.1007","volume":"57","author":[{"given":"Gian Paolo","family":"Caviglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guariglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Troshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Dileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, Bray F, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:335-349.e15.","journal-title":"Gastroenterology"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374.","journal-title":"J Hepatol"},{"key":"1371_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156080","volume":"162","author":"A Armandi","year":"2025","unstructured":"Armandi A, Rosso C, Caviglia GP, et al. An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: trends, pathophysiology and risk-based surveillance. Metabolism. 2025;162:156080.","journal-title":"Metabolism"},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/biomedicines11010166","volume":"11","author":"A Ciancio","year":"2023","unstructured":"Ciancio A, Ribaldone DG, Spertino M, et al. Who should not be surveilled for HCC development after successful therapy with DAAS in advanced chronic hepatitis C? Results of a long-term prospective study. Biomedicines. 2023;11:166.","journal-title":"Biomedicines"},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/v16121899","volume":"16","author":"C Smirne","year":"2024","unstructured":"Smirne C, Crobu MG, Landi I, et al. Chronic hepatitis C infection treated with direct-acting antiviral agents and occurrence\/recurrence of hepatocellular carcinoma: does it still matter? Viruses. 2024;16:1899.","journal-title":"Viruses"},{"key":"1371_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/cancers14030828","volume":"14","author":"GP Caviglia","year":"2022","unstructured":"Caviglia GP, Troshina G, Santaniello U, et al. Long-term hepatocellular carcinoma development and predictive ability of non-invasive scoring systems in patients with HCV-related cirrhosis treated with direct-acting antivirals. Cancers. 2022;14:828.","journal-title":"Cancers"},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hep.32341","volume":"76","author":"I Lockart","year":"2022","unstructured":"Lockart I, Yeo MGH, Hajarizadeh B, et al. Hcc incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology. 2022;76:139\u201354.","journal-title":"Hepatology"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Betse LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264-1278.e4.","journal-title":"Gastroenterology"},{"key":"1371_CR9","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.3748\/wjg.15.3462","volume":"15","author":"S Mueller","year":"2009","unstructured":"Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009;15:3462\u201371.","journal-title":"World J Gastroenterol"},{"key":"1371_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5114\/ceh.2025.151896","volume":"11","author":"AAD Rahadini","year":"2025","unstructured":"Rahadini AAD, Rahadina A. Association between metabolic associated fatty liver disease and HCC risk after SVR in HCV patients: a systematic review and meta-analysis. Clin Exp Hepatol. 2025;11:129\u201336.","journal-title":"Clin Exp Hepatol"},{"key":"1371_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan AR, Nair B, Pradeep GK, et al. The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential. Eur J Med Res. 2024;29:490.","journal-title":"Eur J Med Res"},{"key":"1371_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/apt.18409","volume":"61","author":"GP Caviglia","year":"2025","unstructured":"Caviglia GP, Fariselli P, D\u2019Ambrosio R, et al. Development and validation of a PIVKA-II-based model for HCC risk stratification in patients with HCV-related cirrhosis successfully treated with DAA. Aliment Pharmacol Ther. 2025;61:538\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"1371_CR13","unstructured":"European Association for the Study of the Liver. EASL Policy Statement: Risk\u2010based surveillance for hepatocellular carcinoma among patients with cirrhosis, accessed October 7, 2025, http:\/\/easl.eu\/publication\/easl\u2010policy\u2010statement\u2010risk\u2010based\/."},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-021-08104-z","volume":"21","author":"JY Wang","year":"2021","unstructured":"Wang JY, Wang XK, Zhu GZ, et al. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer. 2021;21:462.","journal-title":"BMC Cancer"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","volume":"100","author":"H Shirakawa","year":"2009","unstructured":"Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403\u20137.","journal-title":"Cancer Sci"},{"key":"1371_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1012418","volume":"12","author":"D Jiang","year":"2022","unstructured":"Jiang D, Zhang Y, Wang Y, et al. Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:1012418.","journal-title":"Front Oncol"},{"key":"1371_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011130","volume":"97","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang M, Ma H, et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis. Medicine. 2018;97:e11130.","journal-title":"Medicine"},{"key":"1371_CR18","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/cancers12113218","volume":"12","author":"GP Caviglia","year":"2020","unstructured":"Caviglia GP, Ciruolo M, Abate ML, et al. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist II and glypican-3 for the detection and prediction of hepatocellular carcinoma in patients with cirrhosis of viral etiology. Cancers. 2020;12:3218.","journal-title":"Cancers"},{"key":"1371_CR19","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/cancers13102305","volume":"13","author":"GP Caviglia","year":"2021","unstructured":"Caviglia GP, Armandi A, Rosso C, et al. Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancers. 2021;13:2305.","journal-title":"Cancers"},{"key":"1371_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/gut.2006.111302","volume":"56","author":"M Fraquelli","year":"2007","unstructured":"Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56:968\u201373.","journal-title":"Gut"},{"key":"1371_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"1371_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"key":"1371_CR23","unstructured":"https:\/\/www.fujirebio.com\/en\/products-solutions\/canag-glypican-3-eia. Accessed on 25 June 2025."},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.23736\/S2724-5985.21.03006-0","volume":"68","author":"A Nicolosi","year":"2022","unstructured":"Nicolosi A, Gaia S, Risso A, et al. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. Minerva Gastroenterol. 2022;68:378\u201386.","journal-title":"Minerva Gastroenterol"},{"key":"1371_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","volume":"81","author":"T Reiberger","year":"2024","unstructured":"Reiberger T, Lens S, Cabibbo G, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81:326\u201344.","journal-title":"J Hepatol"},{"key":"1371_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.clinbiochem.2013.12.007","volume":"47","author":"XF Liu","year":"2014","unstructured":"Liu XF, Hu ZD, Liu XC, et al. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Biochem. 2014;47:196\u2013200.","journal-title":"Clin Biochem"},{"key":"1371_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cas.14251","volume":"111","author":"Y Shimizu","year":"2020","unstructured":"Shimizu Y, Mizuno S, Fujinami N, et al. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2020;111:334\u201342.","journal-title":"Cancer Sci"},{"key":"1371_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.humpath.2007.06.004","volume":"39","author":"HM Abdul-Al","year":"2008","unstructured":"Abdul-Al HM, Makhlouf HR, Wang G, et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209\u201312.","journal-title":"Hum Pathol"},{"key":"1371_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/CBM-190118","volume":"29","author":"G Ricco","year":"2020","unstructured":"Ricco G, Cosma C, Bedogni G, et al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark. 2020;29:189\u201396.","journal-title":"Cancer Biomark"},{"key":"1371_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","volume":"69","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69:1088\u201398.","journal-title":"J Hepatol"},{"key":"1371_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JHC.S116513","volume":"3","author":"Y Wu","year":"2016","unstructured":"Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016;3:63\u20137.","journal-title":"J Hepatocell Carcinoma"},{"key":"1371_CR32","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245\u201354.","journal-title":"Cancer Res"},{"key":"1371_CR33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/hep.25891","volume":"56","author":"L Li","year":"2012","unstructured":"Li L, Jin R, Zhang X, et al. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology. 2012;56:1380\u201390.","journal-title":"Hepatology"},{"key":"1371_CR34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijo.2015.2827","volume":"46","author":"Y Wu","year":"2015","unstructured":"Wu Y, Liu H, Weng H, et al. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol. 2015;46:1275\u201385.","journal-title":"Int J Oncol"},{"key":"1371_CR35","first-page":"497","volume":"28","author":"J Ruan","year":"2011","unstructured":"Ruan J, Liu F, Chen X, et al. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Int J Mol Med. 2011;28:497\u2013503.","journal-title":"Int J Mol Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01371-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:52:14Z","timestamp":1767963134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01371-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01371-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"7 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of \u201cA.O.U. Citt\u00e0 della Salute e della Scienza di Torino\u2014A.O. Ordine Mauriziano\u2014A.S.L. Citt\u00e0 di Torino\u201d (protocol code 0008732, approval date 26 January 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all patients involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6"}}